The Future of Cancer Therapy
Innovative science, breakthrough technology, first-in-class treatments
Pipeline
RGX-104
RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
Pipeline
RGX-202
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Pipeline
RGX-019
RGX-019 is a monoclonal antibody that targets a key pathway that drives tumor progression and metastasis of several cancer types, including triple-negative breast cancer.
Patients
Clinical Trials
We are actively recruiting patients for phase 1 first-in-human, dose escalation and expansion studies of RGX-104 and RGX-202.
Our Science
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
News
-
Rgenix Treats First Patient in Phase 1 Trial of RGX-202
NEW YORK – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced it
-
Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs
Lepu Holdings Limited leads the financing syndicate and is joined by existing major investors Novo Holdings A/S and Sofinnova
-
Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase